---
provider: openai
model: o3-deep-research-2025-06-26
cached: true
start_time: '2025-11-03T21:42:18.871818'
end_time: '2025-11-03T21:42:18.873405'
duration_seconds: 0.0
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: Q9Y6A1
  gene_symbol: POMT1
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    temperature: 0.1
    top_p: 1.0
citation_count: 127
---

## Question

# Gene Research for Functional Annotation

Please provide a comprehensive research report on the gene POMT1 (Q9Y6A1) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function. 

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

# POMT1 (Protein O-Mannosyltransferase 1) – Function, Processes, and Localization

## Overview and Key Function of POMT1  
**POMT1** (UniProt Q9Y6A1) encodes **protein O-mannosyltransferase 1**, an enzyme that catalyzes the addition of mannose sugars to proteins as part of a unique glycosylation pathway. POMT1 is a **glycosyltransferase** that performs **O-linked mannosylation** – it transfers mannose from a lipid-linked donor (dolichol phosphate mannose) to the hydroxyl group of serine or threonine residues on target proteins ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=proteins%20with%20O,24%29%2C%20in%20a)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology)). This reaction represents the first committed step in the **protein O-mannose glycan biosynthesis** pathway, which is crucial for the proper function of several extracellular and cell-surface glycoproteins ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology)). POMT1’s activity is **absolutely dependent on its partner enzyme POMT2** – the two form an **obligate heteromeric complex** in the endoplasmic reticulum (ER) membrane to execute mannose transfer ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=yeast%20PMT4%20and%20PMT2%20O,8%3B%20%2011%20Larsen)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=95,PMC%20free%20article)). Individually, POMT1 or POMT2 cannot efficiently catalyze O-mannosylation; co-expression studies showed that only the POMT1/POMT2 complex has enzymatic activity, confirming the need for both subunits for function ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=yeast%20PMT4%20and%20PMT2%20O,8%3B%20%2011%20Larsen)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=95,PMC%20free%20article)). 

**Enzymatic role:** POMT1 is classified under EC 2.4.1.109 (dolichyl-phosphate-mannose:protein O-mannosyltransferase). Its primary function is to attach a mannose monosaccharide onto specific proteins during or shortly after their synthesis in the ER lumen ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=proteins%20with%20O,24%29%2C%20in%20a)). Unlike more ubiquitous glycosylation events (such as N-linked glycosylation or mucin-type O-GalNAc glycosylation), O-mannosylation is relatively rare and is targeted to particular protein substrates. In human cells, this modification was first recognized in the context of muscle and brain proteins, and POMT1 emerged as a key enzyme when **mutations in POMT1 were found to cause Walker–Warburg syndrome** (WWS) in 2002 ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=Biallelic%20mutations%20in%20Protein%20O,Here%2C%20we)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=Mutations%20in%20the%20O,the%20severe%20condition%20Walker%20Warburg)). WWS is a severe congenital muscular dystrophy with brain and eye abnormalities, and the discovery that POMT1 defects underlie ~20% of WWS cases was pivotal in establishing the enzyme’s fundamental role ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=Biallelic%20mutations%20in%20Protein%20O,Here%2C%20we)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=Mutations%20in%20the%20O,the%20severe%20condition%20Walker%20Warburg)). This finding linked the biochemical activity of POMT1 to critical developmental processes and highlighted that POMT1’s **primary function is essential for normal muscle and neural tissue formation**.

## Substrate Specificity and Biological Substrates  
POMT1/POMT2 broadly recognize protein substrates that require O-mannose glycosylation, but interestingly **no short consensus sequence motif has been identified** for the attachment site. Attempts to pinpoint a specific amino acid sequence that POMT1 targets have been unsuccessful; instead, evidence suggests that **substrate recognition depends on the protein’s folded context or distant structural elements** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=presumed%20heterodimer%20configuration%2C%20analogous%20to,2004%3B%20%2026%20Larsen%20et%C2%A0al)). In other words, POMT1 likely recognizes a combination of structural features on the substrate protein rather than a simple linear motif, making its specificity **more complex and context-dependent** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=presumed%20heterodimer%20configuration%2C%20analogous%20to,2004%3B%20%2026%20Larsen%20et%C2%A0al)). Despite intensive study, the repertoire of known mammalian substrates for POMT1/2 remains limited, indicating that only a subset of proteins receive this modification ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=by%20these%20enzymes%20was%20determined,24%3B%20%2026%20Larsen%20et%C2%A0al)). 

The **best-characterized substrate of POMT1** is **α-dystroglycan (α-DG)**, an extracellular matrix receptor glycoprotein. α-Dystroglycan requires a unique O-mannose-containing glycan (sometimes called the **“matriglycan” structure) to bind extracellular matrix ligands like laminin, agrin, and perlecan ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=Background%3A%20Maintaining%20the%20connection%20between,mannose%20glycan)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology)). POMT1/POMT2 initiate the attachment of mannose on specific threonine residues of α-dystroglycan (notably Thr-317 and Thr-379 in the mature protein, among others), which primes these sites for further elongation into functional glycan structures ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=The%20initial%20mannosylation%20reaction%20of,mannosyltransferase%20activity)). This O-mannosyl glycan is elaborated by a series of enzymes into what is known as the **core M3 glycan**, capped by a repeating disaccharide polymer (matriglycan) that is directly responsible for high-affinity laminin binding ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology)). In simpler terms, **POMT1 places the first “brick” (mannose) in a glycan scaffold on α-dystroglycan, without which the entire carbohydrate structure (and ligand-binding function) cannot be built**. Consistently, **POMT1 mutations lead to hypoglycosylation of α-dystroglycan** – the protein is produced but lacks the necessary sugar chains to tether muscle cells to the basal lamina, resulting in loss of muscle integrity and developmental abnormalities ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=most%20common%20causes%20of%20a,Here%2C%20we)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=biosynthesis%20is%20initiated%20by%20the,system%20and%20skeletal%20muscle%20pathophysiology)).

Beyond α-dystroglycan, several other substrates of POMT1/2 have been identified, underscoring that O-mannosylation, while specialized, is not unique to dystroglycan. For example, certain **receptor protein tyrosine phosphatases (RPTPs)**, such as RPTPζ/phosphacan in the nervous system, carry O-mannose glycan structures that depend on POMT1/2 activity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=Three%20families%20of%20enzymes%20mediating,for%20modifying%20the%20IPT%20domains)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=109,DOI)). These O-mannose glycans on RPTPs have been found to include specific carbohydrate epitopes (like HNK-1) involved in neural development ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=109,DOI)), suggesting a role for POMT1 in modulating cell–cell interactions in the brain. Another reported substrate is the protein **KIAA1549**, identified in glyoproteomic analyses, although its function is less characterized ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=elsewhere%3B%20Nakamura%20et%C2%A0al,24%3B%20%2026%20Larsen%20et%C2%A0al)). The list of POMT1 substrates remains small, but it is growing: **recent research in Drosophila (2023)** showed that a neuronal receptor-like protein, **PTP69D** (a fly homolog of RPTPζ), is modified by POMT and that this modification is required for proper sensory axon guidance ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=,type)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=phosphatases%2C%20is%20a%20functional%20substrate,wiring%20phenotype%2C%20as%20well%20as)). This finding reveals that **POMT1/2’s enzymatic activity extends to cell-surface receptors involved in neural circuit formation**, indicating previously unappreciated substrates and biological contexts for POMT1. In summary, POMT1’s substrate specificity is **broad in function but narrow in occurrence** – it targets a select set of proteins (often large, extracellular or membrane-associated ones) and decorates them with O-mannose as a critical functional modification.

## Cellular Localization and Protein Structure  
POMT1 is a **transmembrane protein** that resides in the **endoplasmic reticulum (ER)**, which is consistent with its role in co-translational protein modification ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=proteins%20with%20O,24%29%2C%20in%20a)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=POMT1,Q8NCR0)). Specifically, POMT1 is an **integral membrane enzyme with multiple membrane-spanning segments**, anchoring it to the ER membrane with its active site facing the ER lumen ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=of%20plexins%20and%20transmembrane%20receptor,%282019)). Bioinformatic analysis and experimental evidence indicate that human POMT1 is 747 amino acids in length and contains at least 10 predicted transmembrane helices ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=POMT1,Q8NCR0)). It belongs to the GT-C superfamily of glycosyltransferases, which are characterized by a conserved **luminal loop containing critical aspartate residues** that coordinate the lipid-linked sugar donor ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=of%20plexins%20and%20transmembrane%20receptor,%282019)). In POMT1 (and POMT2), a pair of conserved acidic residues in the first luminal loop is essential for catalytic activity – these likely form part of the active site that binds dolichol-P-mannose and facilitates mannose transfer ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=of%20plexins%20and%20transmembrane%20receptor,%282019)). This motif is analogous to the **“DXD” or similar catalytic signatures** seen in other glycosyltransferases that bind nucleotide-sugars, although POMT enzymes use a lipid-phosphate sugar donor instead of a nucleotide-sugar.

Structurally, POMT1 and POMT2 are thought to function as a **heterodimeric complex**, and evidence supports a **1:1 stoichiometry** of the two subunits in the active enzyme ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=yeast%20PMT4%20and%20PMT2%20O,8%3B%20%2011%20Larsen)). Studies in model organisms and in vitro have shown that co-expression and physical interaction of POMT1 and POMT2 are required for stability and activity of the complex ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=yeast%20PMT4%20and%20PMT2%20O,8%3B%20%2011%20Larsen)). It mirrors the situation in yeast, where the orthologous enzymes (such as yeast Pmt1 and Pmt2) form a heteromer to initiate O-mannosylation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=comprised%20of%20two%20protein%20O,recognition%20appears%20to%20rely%20on)). Each subunit likely contributes different but complementary elements to the enzyme’s function: one possibility is that one subunit (perhaps POMT2) binds the dolichol-P-mannose donor while the other (POMT1) binds the protein acceptor, or they may form a composite active site together – the precise division of roles is still under investigation. Notably, **POMT1 contains luminal domains predicted to mediate substrate interactions**, including regions homologous to **MIR domains** (mannosyltransferase, inositol 1,4,5-trisphosphate receptor, ryanodine receptor) and **TPR repeats** (tetratricopeptide repeats) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=of%20plexins%20and%20transmembrane%20receptor,%282019)). These domains are thought to help recognize and bind protein substrates, consistent with the idea that **POMT1/2 recognize a folded protein’s surface** rather than a short peptide sequence ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=presumed%20heterodimer%20configuration%2C%20analogous%20to,2004%3B%20%2026%20Larsen%20et%C2%A0al)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=of%20plexins%20and%20transmembrane%20receptor,%282019)). For example, the presence of a MIR domain in each POMT subunit may facilitate binding to specific protein regions, and a recent structural study of a bacterial protein-O-mannosyltransferase revealed a **WW domain-like motif that binds proline-rich sequences** on substrates ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12331936/#:~:text=differences%2C%20MtPMT%20shares%20functional%20homologies,its%20potential%20evolutionary%20linkage%20with)). By analogy, human POMT1 might employ its own specialized domains to dock onto target proteins that often contain regions like mucin-like threonine/serine-rich stretches (as found in α-dystroglycan). 

In terms of subcellular localization, POMT1’s ER residency means it acts **early in the secretory pathway**. It likely modifies nascent polypeptides as they enter the ER lumen during synthesis or soon after, ensuring that the O-mannose is in place before the protein traffics to the Golgi for further processing ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=proteins%20with%20O,24%29%2C%20in%20a)). Immunocytochemistry and cell fractionation studies confirm POMT1 as an ER membrane protein, and it is absent from the plasma membrane or other organelles, aligning with its role in a biosynthetic pathway rather than direct extracellular function ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=proteins%20with%20O,24%29%2C%20in%20a)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=POMT1,Q8NCR0)). Once POMT1 (with POMT2) adds the mannose to the protein, that protein is typically passed to the Golgi apparatus where additional sugars and unique modifications (like N-acetylglucosamine, galactose, and phospho-ribitol) are sequentially added by other enzymes in the pathway ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=The%20asterisks%20mark%20the%20four,in%20all%20the%20lineages%20analysed)). Thus, POMT1 serves as a gatekeeper in the ER, installing a foundational modification without which later enzymatic steps cannot occur. The strict localization to the ER also implies that POMT1 only acts on proteins that enter the conventional secretory route (ER-to-Golgi); cytosolic or nuclear proteins are not substrates since the dolichol-linked mannose donor exists only in the ER membrane.

## Biological Processes and Pathways Involving POMT1  
**Protein O-mannosylation**, driven by POMT1/POMT2, is a conserved post-translational modification that is vital for certain biological processes. The most prominent pathway involving POMT1 is the **glycosylation of α-dystroglycan and related proteins**, which is essential for the structural integrity of muscle tissues and the development of the brain and eye. In this pathway, often termed the **“dystroglycanopathies pathway”** when considering its clinical context, POMT1/2 initiate the synthesis of three recognized subtypes of O-mannose glycan cores (referred to as core M1, M2, and M3 structures) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology)). All three cores start with the same first sugar (mannose) attached by POMT1/2, but they diverge in how the glycan is extended in the Golgi. For instance, in the core M3 pathway that is crucial for muscle function, after POMT1/2 add the O-mannose, the enzyme POMGNT2 (also known as B3GALNT2) adds N-acetylgalactosamine (forming a GalNAc-β1,3-GlcNAc-β1,4-Man trisaccharide) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology)). Additional enzymes then modify this glycan: one (POMK) adds a phosphate-linked xylose (which is actually a ribitol-5-phosphate linkage after further processing), and enzymes called fukutin and FKRP extend a **ribitol phosphate–bound disaccharide**. Finally, the LARGE1 enzyme polymerizes a repeating [-glucuronic acid–β1,3-xylose-α1,3-] unit known as **matriglycan**, which is the structure that directly binds laminin and other ECM proteins ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology)). POMT1’s role is at the very *beginning* of this assembly line – without the initial mannose, none of these downstream elaborations (core M1/M2/M3 or matriglycan) can be built ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=The%20asterisks%20mark%20the%20four,in%20all%20the%20lineages%20analysed)). Therefore, **POMT1-mediated O-mannosylation is a linchpin in the pathway that links intracellular structures to the extracellular matrix**, particularly through the dystroglycan complex.

Biologically, the consequence of proper O-mannosyl glycan assembly on dystroglycan is that muscle cells can anchor to the basement membrane. The α-dystroglycan subunit, heavily glycosylated, binds extracellular laminin, while β-dystroglycan links to the muscle fiber cytoskeleton (via dystrophin). This **dystrophin–glycoprotein complex** is a critical structural unit that stabilizes muscle fibers during contraction. POMT1’s activity (through glycosylating α-dystroglycan) is thus directly tied to **muscle fiber integrity and sarcolemma resilience** ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=Background%3A%20Maintaining%20the%20connection%20between,mannose%20glycan)). In skeletal muscle, improper O-mannosylation leads to a weak link between the muscle cell and the surrounding matrix, causing fibers to degenerate under stress. This is observed in patients and animal models: for example, muscle biopsies from individuals with POMT1 mutations show a loss of the laminin-binding glyco-epitope on α-dystroglycan and dystrophic changes in the tissue ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=years%20after%20the%20identification%20of,also%20a%20marked%20reduction%20of)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=POMT1%2F2%20enzymatic%20activity%20can%20be,rapid%20form%20of%20patient%20screening)). In mice, a **Pomt1 knockout is embryonically lethal** because dystroglycan in the early embryo’s Reichert’s membrane (an initial basement membrane in rodents) is non-functional without O-mannosylation – the embryo cannot properly form this essential basement membrane and fails to develop ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=Targeted%20inactivation%20of%20Pomt1%20has,54)). This striking phenotype underscores that **POMT1-driven glycosylation is essential for basement membrane assembly during development**.

In the nervous system, POMT1’s role is also significant. The brain expresses α-dystroglycan in radial glia and other cells, where it helps organize the extracellular matrix for neuron migration. In disorders like WWS caused by POMT1 mutations, one sees **cobblestone lissencephaly** and other brain malformations due to neurons bypassing a defective pial basement membrane – again a consequence of lost dystroglycan–ECM adhesion ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=the%20attachment%20of%20a%20functional,We%20also%20discovered%20that)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=mutations%20in%20POMT1%20and%20POMT2%2C,Thus)). Additionally, independent of dystroglycan, the finding that **neural receptors like RPTPs require O-mannosylation** suggests POMT1 is involved in **axon guidance and synapse formation** pathways. Recent Drosophila studies demonstrate that without POMT1/2, a subset of axons are misrouted and synaptic connections fail to form correctly, phenotypes that could be rescued by providing the missing enzyme or disrupted similarly by removing the O-mannose-modified receptor ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=phosphatases%2C%20is%20a%20functional%20substrate,wiring%20phenotype%2C%20as%20well%20as)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=match%20at%20L724%20protein%20substrate,functions%20of%20POM%20in%20the)). These data imply that **POMT1-mediated modification of proteins influences cell signaling and tissue patterning** in the nervous system, beyond its structural role in muscle. In summary, the pathways in which POMT1 functions are those that depend on **specific cell–ECM interactions** and **protein–carbohydrate mediated signaling**. Key processes include: muscle maintenance (via dystroglycan glycan–laminin binding), brain cortical layering (via dystroglycan in glia and perhaps other O-mannosylated neural proteins), eye development (the retina has dystroglycan-based connections as well), and aspects of peripheral nerve function (Schwann cells also utilize dystroglycan for myelination). All of these rely on the foundational step carried out by POMT1. Importantly, **POMT1 is one of three known families of mammalian protein O-mannosyltransferases** – the others being the **TMTC1–4 family**, which add O-mannose to cadherins, and a recently discovered enzyme **TMEM260**, which targets plexin and RON/MET receptors ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=Three%20families%20of%20enzymes%20mediating,and%20include%20different)). POMT1/POMT2, however, are uniquely responsible for the dystroglycan-type pathways and certain other substrates, and thus occupy a non-redundant niche in human biology ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=Three%20families%20of%20enzymes%20mediating,and%20include%20different)).

## Clinical Significance and Disease Associations  
Given its critical role in glycosylation, **POMT1 is classified as a disease-related gene**, and indeed multiple human diseases are directly caused by loss-of-function mutations in POMT1. The **muscular dystrophy–dystroglycanopathy syndromes** are a spectrum of autosomal recessive disorders caused by defects in the glycosylation of α-dystroglycan, and POMT1 mutations are a well-established cause of several forms of these conditions. At the severe end is **Walker–Warburg Syndrome (WWS)** (also termed *Type A dystroglycanopathy* when classified by genetic cause), which manifests as congenital muscular dystrophy with brain and eye malformations. POMT1 was one of the first genes identified in WWS patients – around *20% of WWS cases have mutations in POMT1* ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=Mutations%20in%20the%20O,the%20severe%20condition%20Walker%20Warburg)), making it a major contributor to this lethal early-onset disorder. Infants with POMT1-related WWS often have nearly complete loss of functional glycosylation on α-dystroglycan in muscle tissue ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=years%20after%20the%20identification%20of,also%20a%20marked%20reduction%20of)). This leads to severe muscle weakness, contractures, brain structural defects (like cobblestone lissencephaly and hydrocephalus), retinal dysplasia, and typically death in early childhood. At the milder end of the spectrum, **limb-girdle muscular dystrophy type 2K (LGMD2K)** is caused by hypomorphic mutations in POMT1 that allow partial enzyme function ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=match%20at%20L195%20%2848%2C%2049%29,mutations%20have%20also%20been%20recently)). Patients with LGMD2K have later-onset, milder muscle weakness (compatible with walking in childhood), but notably often present with intellectual disability or microcephaly even if brain MRI is normal ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=%2848%2C%2049%29,mutations%20have%20also%20been%20recently)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=secondary%20to%20specific%20gene%20mutations,These%20results%20may)). This contrasts with mutations in some other dystroglycanopathy genes (like FKRP) that can cause purely muscular phenotypes – **POMT1 mutations, even milder ones, tend to have CNS involvement** more frequently ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=match%20at%20L372%20secondary%20to,These%20results%20may)). This clinical observation aligns with the importance of POMT1 in both muscle and brain developmental pathways.

Other intermediate phenotypes linked to POMT1 include **Muscle-Eye-Brain disease (MEB)** and **congenital muscular dystrophy type 1K (MDC1K)** – nomenclature has evolved, but essentially these are dystroglycanopathies with severity between WWS and LGMD. Common to all is that **loss of POMT1 activity leads to a failure to glycosylate dystroglycan**, which can be detected by immunostaining for glycan-dependent epitopes on α-dystroglycan in patient muscle biopsies ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=years%20after%20the%20identification%20of,also%20a%20marked%20reduction%20of)). This biochemical assay (using antibodies that recognize fully glycosylated dystroglycan versus core protein) is often used alongside genetics to confirm a POMT1-related dystroglycanopathy. Interesting data from patient cohorts show that among known dystroglycanopathy genes, **POMT1 is one of the more frequently mutated** (besides a few others like POMT2 and FKRP). For example, in a study of 92 patients with clinical dystroglycanopathy (various severities), **POMT1 mutations were identified in 8 of the cases (~9%)** and POMT2 in 9 cases, making POMT1/POMT2 defects a significant subset of this population ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=32%20were%20novel,Table%201)). This underscores the real-world importance of POMT1: it is regularly screened in diagnostics for congenital muscular dystrophy. Indeed, genetic testing panels for muscular dystrophy now routinely include POMT1 (and POMT2), and assays measuring POMT enzymatic activity in patient cells (fibroblasts or lymphoblasts) have been developed as a diagnostic tool ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=match%20at%20L203%20POMT1%2F2%20enzymatic,rapid%20form%20of%20patient%20screening)). Reduced POMT activity in patient-derived cells correlates with POMT1 or POMT2 mutations and can help confirm pathogenicity of novel variants ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=match%20at%20L203%20POMT1%2F2%20enzymatic,rapid%20form%20of%20patient%20screening)). 

Beyond muscle disease, the full spectrum of POMT1’s clinical significance is still being uncovered. There are indications that POMT1 variants could contribute to certain neurodevelopmental conditions given its role in neural protein glycosylation, though the primary phenotype remains neuromuscular. In terms of **maternal effect and development**, a recent zebrafish model revealed an intriguing aspect: **maternal deposit of pomt1 mRNA** in the egg can transiently compensate for zygotic loss of POMT1 during early development ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=characterized%20and%20validated%20a%20model,only%20leading%20to%20loss%20of)). In zebrafish engineered to lack functional pomt1, early embryonic development appeared normal if the mother was heterozygous (supplying some pomt1 transcript to the embryo), delaying the onset of dystroglycanopathy phenotypes ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=characterized%20and%20validated%20a%20model,Our%20findings%20show%20that%20it)). However, by a week post-fertilization, fish lacking pomt1 displayed muscular dystrophy, eye defects, and axonal pathfinding errors analogous to human disease features ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=extracellular%20matrix%20%28ECM%29,Muscle%20disease%2C%20retinal)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=dystroglycanopathies%20can%20be%20recapitulated%20in,of%20maternal%20mRNA%20while%20developing)). This model confirms the central role of POMT1 in muscle and brain development and provides an *in vivo* platform to study disease mechanisms and potential therapies.

From a therapeutic standpoint, **treating POMT1-related conditions** is challenging because one must restore a complex glycosylation event rather than simply replace a missing protein. There is currently no cure for POMT1-deficient dystroglycanopathies, but research is exploring ways to bypass or supplement parts of the glycosylation pathway. For instance, in related glycosylation disorders, substrate supplementation therapy has been attempted: a **2022 study showed that providing a precursor (CDP-ribitol) can rescue glycosylation in a mouse model of another dystroglycanopathy** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=150,PMC%20free%20article)). While that study was targeting a different enzyme (ISPD, which supplies ribitol-phosphate for later steps in the pathway), it opens the door to the idea that *some effects of POMT1 loss might be mitigated by enhancing downstream glycosylation* if the initial mannose can be bypassed or if small amounts of activity can be boosted. Another line of research is gene therapy – introducing a correct POMT1 gene into affected muscle. This is still in very early stages due to the large size of the gene and the need for regulated expression in many tissues (including brain). However, as a proof of concept, viral delivery of glycosylation pathway genes (like LARGE) to muscle has shown restored glycosylation in animal models ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=65,PMC%20free%20article)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=79,PMC%20free)). For POMT1, any therapy would need to be systemic and probably very early in development to prevent the profound developmental defects. 

In summary, POMT1’s clinical significance is exemplified by the **dystroglycanopathy disorders**: it is a gene that when mutated causes a continuum of syndromes from lethal congenital disease to milder muscular dystrophy with intellectual impairment. Its identification in patients has also provided molecular confirmation that O-mannosylation is not just a biochemical curiosity but a pathway absolutely required for human health. The **frequency of POMT1 mutations among dystroglycanopathy patients** (substantial, though not the highest) means that understanding POMT1 function is directly relevant to a notable subset of muscular dystrophy cases worldwide ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=32%20were%20novel,Table%201)). 

## Recent Research and Developments (2023–2024)  
Research in the last few years has significantly advanced our understanding of POMT1 and protein O-mannosylation, while also highlighting key gaps. A comprehensive review in *Glycobiology* (August 2023) notes that despite decades since POMT1’s discovery, **major questions remain about how POMT1/POMT2 select their substrates and how exactly the complex carries out catalysis** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=et%C2%A0al,limited%20structure%E2%80%93function%20information%20on%20different)). The review emphasizes that only a **paucity of substrates** have been definitively identified for mammalian POMT1/2 and that we lack high-resolution structural information on these enzymes ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=et%C2%A0al,limited%20structure%E2%80%93function%20information%20on%20different)). This has made it challenging to predict which proteins might be O-mannosylated or to design precise interventions. *Expert opinion:* as Panin and colleagues (2023) summarize, *“the mechanisms of protein O-mannosylation functions are still not well understood”* due to the limited number of characterized substrates and the absence of detailed structure–function data ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=et%C2%A0al,limited%20structure%E2%80%93function%20information%20on%20different)). This acknowledgment from experts underscores the current frontier of POMT1 research: figuring out the rules of its substrate recognition and the structure of the enzyme complex itself.

On the substrate front, **new substrates and biological roles for POMT1 are being uncovered**. The 2023 study by Monagas-Valentin *et al.* (J. Biol. Chem. 2023) in fruit flies is one such breakthrough. By using Drosophila genetics, they demonstrated that the receptor tyrosine phosphatase **PTP69D is O-mannosylated by the fly POMT1/2 orthologs**, and that this modification is crucial for neural wiring in the developing nervous system ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=,type)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=phosphatases%2C%20is%20a%20functional%20substrate,wiring%20phenotype%2C%20as%20well%20as)). This finding is important because it expands the scope of POMT1’s function beyond the classic dystroglycan paradigm. It suggests that even in mammals, other cell-surface proteins involved in cell signaling or adhesion (like the mammalian homolog RPTPζ/Phosphacan) could be regulated by O-mannosylation. In fact, earlier studies had hinted at this by identifying O-mannose–linked glycans on RPTPζ in mouse brain ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=109,DOI)), and the new work solidifies the idea that **POMT1-mediated glycosylation has roles in the nervous system’s development and possibly in synaptic function**. Researchers are now actively looking for additional substrates using glycoproteomics and bioinformatic prediction of the “acceptor sites” for POMT1. The concept of a **“O-mannosylation motif”** is being revisited with a structural lens – scientists are examining whether specific domains (like Ig domains or cadherin repeats) in proteins tend to carry O-mannose when POMT1 is present ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=,type)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=elsewhere%3B%20Nakamura%20et%C2%A0al,2017b%20%3B%20%2018)).

In terms of structural biology, there have been significant advances. While human POMT1 itself has not yet been solved in atomic detail, **analogs from other organisms have shed light on the enzyme’s architecture**. In 2018–2019, cryo-EM structures of related **yeast PMT complexes** and other GT-C family enzymes began to emerge ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=yeast%20PMT4%20and%20PMT2%20O,8%3B%20%2011%20Larsen)). More recently, in 2023, a detailed structure of a **Mycobacterium tuberculosis protein O-mannosyltransferase (MtPmt)** was reported ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12331936/#:~:text=We%20have%20previously%20demonstrated%20that,like%20domain)). This bacterial enzyme shares core functional homology with eukaryotic POMTs, and the study revealed a surprise: a **WW domain-like fold** embedded in the enzyme that is responsible for binding proline-rich segments of substrate proteins ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12331936/#:~:text=differences%2C%20MtPMT%20shares%20functional%20homologies,its%20potential%20evolutionary%20linkage%20with)). This was the first identification of a dedicated substrate-recognition module in an O-mannosyltransferase. The presence of a WW-like domain in a prokaryotic enzyme raises intriguing questions about whether eukaryotic POMT1/POMT2 have analogous domains or motifs that confer substrate specificity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12331936/#:~:text=differences%2C%20MtPMT%20shares%20functional%20homologies,its%20potential%20evolutionary%20linkage%20with)). It’s known that POMT1 contains regions (MIR/TPR domains) that likely play a role in substrate binding ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=of%20plexins%20and%20transmembrane%20receptor,%282019)), and these new findings encourage deeper investigation into those regions. Researchers may leverage computational modeling (e.g., AlphaFold predictions) and mutagenesis to map substrate-binding surfaces on POMT1. Indeed, as of mid-2023, AlphaFold’s model of human POMT1 is available (albeit at modest confidence), providing a starting point for hypotheses on how the POMT1/POMT2 complex might arrange itself in the membrane and engage with polypeptide substrates.

Another area of development is **therapeutic research** for POMT1-related conditions. While no direct therapy for POMT1 deficiency is in clinical trials yet, 2023 saw continued progress in therapies for dystroglycanopathies that could be relevant. For example, the use of **gene editing tools** (like CRISPR/Cas9) in patient-derived cells has been explored to correct certain mutations in glycosylation genes. Also, as mentioned, substrate supplementation strategies are being optimized: a 2023 *Nature Communications* study demonstrated a **CDP-ribitol prodrug** can increase glycosylation in an animal model of a related enzyme deficiency ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=150,PMC%20free%20article)). This success suggests that if a safe metabolic supplementation could be found for the O-mannose pathway, it might help residual POMT1/POMT2 activity in mild cases or at least improve glycosylation from partially active mutant enzymes. Moreover, clinical research networks are expanding patient registries for dystroglycanopathies, which helps in gathering natural history data and will be crucial for any future trials. One practical real-world development is improved **diagnostic efficiency** – as of 2023, many centers use next-generation sequencing gene panels to diagnose unexplained congenital muscular dystrophies, and POMT1 is a staple on these panels. There’s also interest in newborn screening: since the most severe POMT1 mutations cause WWS (which often presents at birth), early genetic identification could be useful for family counseling, even if treatments are supportive.

Finally, an interesting biological development is the discovery of **O-mannosylation in unexpected contexts**. For instance, one recent report found evidence of O-mannose glycan on a **cytosolic protein in yeast** (indicating a possible new pathway or a moonlighting activity of PMTs), though this is still under scrutiny. In higher organisms, the O-mannose glycan has been implicated in forming binding sites for certain carbohydrate-recognizing proteins (like lectins or galectins) on the cell surface ([academic.oup.com](https://academic.oup.com/glycob/article-abstract/27/9/806/3914559#:~:text=Recent%20advancements%20in%20understanding%20mammalian,283%20%3A%2033026%20%E2%80%93)), hinting that POMT1’s products might have signaling roles. As research continues, the paradigm of POMT1 is shifting from “an enzyme needed only for dystroglycan” to **“a multifaceted glycosyltransferase important in multiple organ systems.”** 

## Conclusion and Expert Analysis  
**POMT1 (protein O-mannosyltransferase 1)** is a crucial enzyme in human biology that catalyzes the first step of O-mannose type protein glycosylation. Its **primary function** is to transfer mannose from dolichol-phosphate-mannose to specific serine/threonine residues on target proteins, a reaction that requires the formation of a POMT1–POMT2 enzyme complex in the ER ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=proteins%20with%20O,24%29%2C%20in%20a)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=yeast%20PMT4%20and%20PMT2%20O,8%3B%20%2011%20Larsen)). Through this activity, POMT1 enables the biosynthesis of unique glycans (such as those on α-dystroglycan) that mediate cell–matrix adhesion and signaling. The **cellular locale** of POMT1 in the ER membrane is perfectly suited to modify nascent secretory proteins, and its multi-pass membrane structure with conserved acidic residues reflects a sophisticated mechanism adapted for a lipid-linked sugar donor ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=of%20plexins%20and%20transmembrane%20receptor,%282019)). Current understanding, supported by both biochemical and genetic evidence, positions POMT1 as an **indispensable component of the dystroglycan glycosylation pathway** – without it, the “ligand-binding sugar code” on dystroglycan and some other proteins cannot be written, leading to devastating consequences for muscle, brain, and eye development ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=most%20common%20causes%20of%20a,Here%2C%20we)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology)).

Authoritative reviews and primary studies converge on the view that **POMT1’s role is specific but significant**. As noted by experts, the enzyme’s **substrate scope is limited to a subset of glycoproteins** (no ubiquitous consensus sequence has been found), yet for those substrates POMT1-mediated mannosylation is *essential* ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=presumed%20heterodimer%20configuration%2C%20analogous%20to,2004%3B%20%2026%20Larsen%20et%C2%A0al)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=elsewhere%3B%20Nakamura%20et%C2%A0al,24%3B%20%2026%20Larsen%20et%C2%A0al)). This specificity is a double-edged sword: it means loss of POMT1 doesn’t broadly disrupt all glycoproteins (explaining why life can continue in milder mutants), but it critically cripples certain proteins (explaining the particular pattern of disease in muscle and brain). The **evidence base** for POMT1’s function is robust – ranging from in vitro enzymatic assays and cell-based activity measurements to in vivo animal knockout models and human genetics. For example, the requirement of **co-expressing POMT1 with POMT2 to reconstitute O-mannosylation activity** in cell experiments was a key piece of evidence confirming POMT1’s enzymatic identity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=yeast%20PMT4%20and%20PMT2%20O,8%3B%20%2011%20Larsen)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=95,PMC%20free%20article)). In vivo, the phenotypes of POMT1 loss (embryonic lethality in mice, severe muscular dystrophy in zebrafish, and WWS in humans) all reinforce the notion that the glycan product of POMT1 is non-redundant and fundamental ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=Targeted%20inactivation%20of%20Pomt1%20has,54)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=Biallelic%20mutations%20in%20Protein%20O,Here%2C%20we)). 

From an evolutionary perspective, POMT1 is **highly conserved among metazoans**, underlining its importance. Orthologs of POMT1/POMT2 can be traced back to single-celled ancestors of animals, and most complex animals retain these genes ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=comprised%20of%20two%20protein%20O,recognition%20appears%20to%20rely%20on)). Some organisms like *Drosophila* have POMT1/2 and show developmental defects when they are mutated (e.g., the “rotated abdomen” phenotype in flies) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=Drosophila%20orthologues%20of%20mammalian%20POMT1,Blanco%20and)). Interestingly, a few lineages (like nematodes and plants) appear to lack POMT1/2 and correspondingly do not perform protein O-mannosylation on dystroglycan ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=match%20at%20L558%20relevantly%2C%20POMT1,mannosylation%20step%20cannot%20take%20place)). In those cases, evolution may have altered or circumvented the dystroglycan–ECM linkage mechanism, but in vertebrates and many other phyla, the **POMT1-dependent pathway is evidently crucial** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=The%20asterisks%20mark%20the%20four,in%20all%20the%20lineages%20analysed)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=Nematoda%2C%20there%20are%20no%20POMT1%2FPOMT2,and%20to%20a%20different%20glycosylation)). This conservation also explains why the most severe human diseases (WWS, etc.) are tied to the most conserved enzymes (POMT1, POMT2, POMGNT1, LARGE1) in the dystroglycan glycosylation cascade ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=The%20asterisks%20mark%20the%20four,in%20all%20the%20lineages%20analysed)).

In conclusion, POMT1 functions as a **gatekeeper enzyme for a specialized glycosylation pathway** that has outsized importance for muscle integrity and neural development. Its gene product works in the ER to install a single sugar that becomes the nucleation point for complex glycans enabling cell–matrix cohesion. Modern research (2023–2024) continues to unravel additional roles and substrates for POMT1, suggesting we are only beginning to appreciate the full spectrum of its biological significance. By integrating biochemical, structural, and genetic approaches, scientists aim to answer the remaining questions: how does POMT1 recognize its diverse substrates, how do POMT1 and POMT2 coordinate catalysis, and can we modulate this enzyme complex for therapeutic benefit? Addressing these questions will not only illuminate fundamental aspects of cell biology but also pave the way for strategies to treat the **dystroglycanopathies** and other conditions arising from POMT1 dysfunction. As of now, the consensus in the expert community is that **POMT1 is an indispensable enzyme**, acting quietly behind the scenes of protein maturation, but absolutely required for the grand structure that is a functioning human organism ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=most%20common%20causes%20of%20a,Here%2C%20we)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology)).

**References:** (Key sources are listed with publication details for reference)  

- Koff et al., *Glycobiology*, 2023 – “Protein O-mannosylation: one sugar, several pathways, many functions” ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=proteins%20with%20O,24%29%2C%20in%20a)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=presumed%20heterodimer%20configuration%2C%20analogous%20to,2004%3B%20%2026%20Larsen%20et%C2%A0al)) (Comprehensive review of O-mannosylation, substrate scope, and enzyme families)  
- Manya et al., *PNAS*, 2004 – Demonstration that co-expression of POMT1 and POMT2 is required for O-mannosyltransferase activity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=yeast%20PMT4%20and%20PMT2%20O,8%3B%20%2011%20Larsen)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=95,PMC%20free%20article)).  
- Beltrán-Valero de Bernabé et al., *Am. J. Hum. Genet.*, 2002 – Identification of POMT1 mutations causing Walker-Warburg syndrome ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=Biallelic%20mutations%20in%20Protein%20O,Here%2C%20we)).  
- Muntoni et al., *Brain*, 2010 – “Muscular dystrophies due to defective glycosylation of dystroglycan” (clinical spectrum and frequency of POMT1 mutations) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=Mutations%20in%20the%20O,the%20severe%20condition%20Walker%20Warburg)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=32%20were%20novel,Table%201)).  
- Bigotti & Brancaccio, *Open Biol*, 2021 – Evolutionary analysis of dystroglycan glycosylation enzymes, noting POMT1/2 conservation and function in glycoepitope synthesis ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=The%20initial%20mannosylation%20reaction%20of,mannosyltransferase%20activity)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=POMT1,Q8NCR0)).  
- Messina et al., *Disease Models & Mech.*, 2023 – Zebrafish pomt1 knockout model recapitulating dystroglycanopathy phenotypes ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=Biallelic%20mutations%20in%20Protein%20O,Here%2C%20we)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=extracellular%20matrix%20%28ECM%29,Muscle%20disease%2C%20retinal)).  
- Monagas-Valentin et al., *J. Biol. Chem.*, 2023 – Discovery that Drosophila PTP69D (RPTPζ analog) is a substrate of POMT1/2, implicating O-mannosylation in axon guidance ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=,type)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=phosphatases%2C%20is%20a%20functional%20substrate,wiring%20phenotype%2C%20as%20well%20as)).  
- Kuwabara et al., *PNAS*, 2016 – Characterization of the glycosylation sites on α-dystroglycan (showing specific Thr residues modified by POMT1/2) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=The%20initial%20mannosylation%20reaction%20of,mannosyltransferase%20activity)).  
- Zhu et al., *Nat. Commun.*, 2022 – Therapeutic CDP-ribitol prodrug in mouse model (indirectly relevant to POMT1 pathway) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=150,PMC%20free%20article)).  
- Additional references are embedded in text as inline citations for specific claims (publication dates provided where available).

## Citations

1. AnnotationURLCitation(end_index=655, start_index=533, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=proteins%20with%20O,24%29%2C%20in%20a')
2. AnnotationURLCitation(end_index=806, start_index=656, title='Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology')
3. AnnotationURLCitation(end_index=1163, start_index=1013, title='Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology')
4. AnnotationURLCitation(end_index=1496, start_index=1360, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=yeast%20PMT4%20and%20PMT2%20O,8%3B%20%2011%20Larsen')
5. AnnotationURLCitation(end_index=1605, start_index=1497, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=95,PMC%20free%20article')
6. AnnotationURLCitation(end_index=1955, start_index=1819, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=yeast%20PMT4%20and%20PMT2%20O,8%3B%20%2011%20Larsen')
7. AnnotationURLCitation(end_index=2064, start_index=1956, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=95,PMC%20free%20article')
8. AnnotationURLCitation(end_index=2447, start_index=2325, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=proteins%20with%20O,24%29%2C%20in%20a')
9. AnnotationURLCitation(end_index=3001, start_index=2869, title='Removal of pomt1 in zebrafish leads to loss of α-dystroglycan glycosylation and dystroglycanopathy phenotypes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=Biallelic%20mutations%20in%20Protein%20O,Here%2C%20we')
10. AnnotationURLCitation(end_index=3154, start_index=3002, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=Mutations%20in%20the%20O,the%20severe%20condition%20Walker%20Warburg')
11. AnnotationURLCitation(end_index=3490, start_index=3358, title='Removal of pomt1 in zebrafish leads to loss of α-dystroglycan glycosylation and dystroglycanopathy phenotypes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=Biallelic%20mutations%20in%20Protein%20O,Here%2C%20we')
12. AnnotationURLCitation(end_index=3643, start_index=3491, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=Mutations%20in%20the%20O,the%20severe%20condition%20Walker%20Warburg')
13. AnnotationURLCitation(end_index=4492, start_index=4311, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=presumed%20heterodimer%20configuration%2C%20analogous%20to,2004%3B%20%2026%20Larsen%20et%C2%A0al')
14. AnnotationURLCitation(end_index=4874, start_index=4693, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=presumed%20heterodimer%20configuration%2C%20analogous%20to,2004%3B%20%2026%20Larsen%20et%C2%A0al')
15. AnnotationURLCitation(end_index=5203, start_index=5043, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=by%20these%20enzymes%20was%20determined,24%3B%20%2026%20Larsen%20et%C2%A0al')
16. AnnotationURLCitation(end_index=5663, start_index=5511, title='Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=Background%3A%20Maintaining%20the%20connection%20between,mannose%20glycan')
17. AnnotationURLCitation(end_index=5814, start_index=5664, title='Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology')
18. AnnotationURLCitation(end_index=6221, start_index=6061, title='High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=The%20initial%20mannosylation%20reaction%20of,mannosyltransferase%20activity')
19. AnnotationURLCitation(end_index=6599, start_index=6449, title='Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology')
20. AnnotationURLCitation(end_index=7177, start_index=7054, title='Removal of pomt1 in zebrafish leads to loss of α-dystroglycan glycosylation and dystroglycanopathy phenotypes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=most%20common%20causes%20of%20a,Here%2C%20we')
21. AnnotationURLCitation(end_index=7348, start_index=7178, title='Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=biosynthesis%20is%20initiated%20by%20the,system%20and%20skeletal%20muscle%20pathophysiology')
22. AnnotationURLCitation(end_index=7870, start_index=7704, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=Three%20families%20of%20enzymes%20mediating,for%20modifying%20the%20IPT%20domains')
23. AnnotationURLCitation(end_index=7963, start_index=7871, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=109,DOI')
24. AnnotationURLCitation(end_index=8192, start_index=8100, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=109,DOI')
25. AnnotationURLCitation(end_index=8568, start_index=8411, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=elsewhere%3B%20Nakamura%20et%C2%A0al,24%3B%20%2026%20Larsen%20et%C2%A0al')
26. AnnotationURLCitation(end_index=8939, start_index=8849, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=,type')
27. AnnotationURLCitation(end_index=9113, start_index=8940, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=phosphatases%2C%20is%20a%20functional%20substrate,wiring%20phenotype%2C%20as%20well%20as')
28. AnnotationURLCitation(end_index=9924, start_index=9802, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=proteins%20with%20O,24%29%2C%20in%20a')
29. AnnotationURLCitation(end_index=10021, start_index=9925, title='High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=POMT1,Q8NCR0')
30. AnnotationURLCitation(end_index=10331, start_index=10193, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=of%20plexins%20and%20transmembrane%20receptor,%282019')
31. AnnotationURLCitation(end_index=10590, start_index=10494, title='High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=POMT1,Q8NCR0')
32. AnnotationURLCitation(end_index=10930, start_index=10792, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=of%20plexins%20and%20transmembrane%20receptor,%282019')
33. AnnotationURLCitation(end_index=11297, start_index=11159, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=of%20plexins%20and%20transmembrane%20receptor,%282019')
34. AnnotationURLCitation(end_index=11833, start_index=11697, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=yeast%20PMT4%20and%20PMT2%20O,8%3B%20%2011%20Larsen')
35. AnnotationURLCitation(end_index=12140, start_index=12004, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=yeast%20PMT4%20and%20PMT2%20O,8%3B%20%2011%20Larsen')
36. AnnotationURLCitation(end_index=12440, start_index=12282, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=comprised%20of%20two%20protein%20O,recognition%20appears%20to%20rely%20on')
37. AnnotationURLCitation(end_index=13192, start_index=13054, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=of%20plexins%20and%20transmembrane%20receptor,%282019')
38. AnnotationURLCitation(end_index=13564, start_index=13383, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=presumed%20heterodimer%20configuration%2C%20analogous%20to,2004%3B%20%2026%20Larsen%20et%C2%A0al')
39. AnnotationURLCitation(end_index=13703, start_index=13565, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=of%20plexins%20and%20transmembrane%20receptor,%282019')
40. AnnotationURLCitation(end_index=14169, start_index=13979, title='Structural Insights into the Protein Mannosyltransferase from Mycobacterium tuberculosis reveal a WW-Domain-Like Protein Motif in Bacteria - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12331936/#:~:text=differences%2C%20MtPMT%20shares%20functional%20homologies,its%20potential%20evolutionary%20linkage%20with')
41. AnnotationURLCitation(end_index=14806, start_index=14684, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=proteins%20with%20O,24%29%2C%20in%20a')
42. AnnotationURLCitation(end_index=15176, start_index=15054, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=proteins%20with%20O,24%29%2C%20in%20a')
43. AnnotationURLCitation(end_index=15273, start_index=15177, title='High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=POMT1,Q8NCR0')
44. AnnotationURLCitation(end_index=15701, start_index=15551, title='Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology')
45. AnnotationURLCitation(end_index=15858, start_index=15702, title='High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=The%20asterisks%20mark%20the%20four,in%20all%20the%20lineages%20analysed')
46. AnnotationURLCitation(end_index=17066, start_index=16916, title='Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology')
47. AnnotationURLCitation(end_index=17590, start_index=17440, title='Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology')
48. AnnotationURLCitation(end_index=18184, start_index=18034, title='Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology')
49. AnnotationURLCitation(end_index=18511, start_index=18361, title='Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology')
50. AnnotationURLCitation(end_index=18668, start_index=18512, title='High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=The%20asterisks%20mark%20the%20four,in%20all%20the%20lineages%20analysed')
51. AnnotationURLCitation(end_index=19563, start_index=19411, title='Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=Background%3A%20Maintaining%20the%20connection%20between,mannose%20glycan')
52. AnnotationURLCitation(end_index=20105, start_index=19945, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=years%20after%20the%20identification%20of,also%20a%20marked%20reduction%20of')
53. AnnotationURLCitation(end_index=20273, start_index=20106, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=POMT1%2F2%20enzymatic%20activity%20can%20be,rapid%20form%20of%20patient%20screening')
54. AnnotationURLCitation(end_index=20693, start_index=20564, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=Targeted%20inactivation%20of%20Pomt1%20has,54')
55. AnnotationURLCitation(end_index=21408, start_index=21261, title='Removal of pomt1 in zebrafish leads to loss of α-dystroglycan glycosylation and dystroglycanopathy phenotypes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=the%20attachment%20of%20a%20functional,We%20also%20discovered%20that')
56. AnnotationURLCitation(end_index=21537, start_index=21409, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=mutations%20in%20POMT1%20and%20POMT2%2C,Thus')
57. AnnotationURLCitation(end_index=22181, start_index=22008, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=phosphatases%2C%20is%20a%20functional%20substrate,wiring%20phenotype%2C%20as%20well%20as')
58. AnnotationURLCitation(end_index=22338, start_index=22182, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=match%20at%20L724%20protein%20substrate,functions%20of%20POM%20in%20the')
59. AnnotationURLCitation(end_index=23516, start_index=23362, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=Three%20families%20of%20enzymes%20mediating,and%20include%20different')
60. AnnotationURLCitation(end_index=23839, start_index=23685, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=Three%20families%20of%20enzymes%20mediating,and%20include%20different')
61. AnnotationURLCitation(end_index=24809, start_index=24657, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=Mutations%20in%20the%20O,the%20severe%20condition%20Walker%20Warburg')
62. AnnotationURLCitation(end_index=25164, start_index=25004, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=years%20after%20the%20identification%20of,also%20a%20marked%20reduction%20of')
63. AnnotationURLCitation(end_index=25682, start_index=25520, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=match%20at%20L195%20%2848%2C%2049%29,mutations%20have%20also%20been%20recently')
64. AnnotationURLCitation(end_index=26027, start_index=25885, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=%2848%2C%2049%29,mutations%20have%20also%20been%20recently')
65. AnnotationURLCitation(end_index=26178, start_index=26028, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=secondary%20to%20specific%20gene%20mutations,These%20results%20may')
66. AnnotationURLCitation(end_index=26529, start_index=26389, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=match%20at%20L372%20secondary%20to,These%20results%20may')
67. AnnotationURLCitation(end_index=27269, start_index=27109, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=years%20after%20the%20identification%20of,also%20a%20marked%20reduction%20of')
68. AnnotationURLCitation(end_index=27992, start_index=27881, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=32%20were%20novel,Table%201')
69. AnnotationURLCitation(end_index=28515, start_index=28350, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=match%20at%20L203%20POMT1%2F2%20enzymatic,rapid%20form%20of%20patient%20screening')
70. AnnotationURLCitation(end_index=28823, start_index=28658, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=match%20at%20L203%20POMT1%2F2%20enzymatic,rapid%20form%20of%20patient%20screening')
71. AnnotationURLCitation(end_index=29510, start_index=29356, title='Removal of pomt1 in zebrafish leads to loss of α-dystroglycan glycosylation and dystroglycanopathy phenotypes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=characterized%20and%20validated%20a%20model,only%20leading%20to%20loss%20of')
72. AnnotationURLCitation(end_index=29894, start_index=29738, title='Removal of pomt1 in zebrafish leads to loss of α-dystroglycan glycosylation and dystroglycanopathy phenotypes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=characterized%20and%20validated%20a%20model,Our%20findings%20show%20that%20it')
73. AnnotationURLCitation(end_index=30206, start_index=30063, title='Removal of pomt1 in zebrafish leads to loss of α-dystroglycan glycosylation and dystroglycanopathy phenotypes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=extracellular%20matrix%20%28ECM%29,Muscle%20disease%2C%20retinal')
74. AnnotationURLCitation(end_index=30380, start_index=30207, title='Removal of pomt1 in zebrafish leads to loss of α-dystroglycan glycosylation and dystroglycanopathy phenotypes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=dystroglycanopathies%20can%20be%20recapitulated%20in,of%20maternal%20mRNA%20while%20developing')
75. AnnotationURLCitation(end_index=31244, start_index=31135, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=150,PMC%20free%20article')
76. AnnotationURLCitation(end_index=32076, start_index=31968, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=65,PMC%20free%20article')
77. AnnotationURLCitation(end_index=32175, start_index=32077, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=79,PMC%20free')
78. AnnotationURLCitation(end_index=33085, start_index=32974, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=32%20were%20novel,Table%201')
79. AnnotationURLCitation(end_index=33680, start_index=33517, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=et%C2%A0al,limited%20structure%E2%80%93function%20information%20on%20different')
80. AnnotationURLCitation(end_index=34034, start_index=33871, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=et%C2%A0al,limited%20structure%E2%80%93function%20information%20on%20different')
81. AnnotationURLCitation(end_index=34566, start_index=34403, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=et%C2%A0al,limited%20structure%E2%80%93function%20information%20on%20different')
82. AnnotationURLCitation(end_index=35281, start_index=35191, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=,type')
83. AnnotationURLCitation(end_index=35455, start_index=35282, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=phosphatases%2C%20is%20a%20functional%20substrate,wiring%20phenotype%2C%20as%20well%20as')
84. AnnotationURLCitation(end_index=35960, start_index=35868, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=109,DOI')
85. AnnotationURLCitation(end_index=36592, start_index=36502, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=,type')
86. AnnotationURLCitation(end_index=36734, start_index=36593, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=elsewhere%3B%20Nakamura%20et%C2%A0al,2017b%20%3B%20%2018')
87. AnnotationURLCitation(end_index=37203, start_index=37067, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=yeast%20PMT4%20and%20PMT2%20O,8%3B%20%2011%20Larsen')
88. AnnotationURLCitation(end_index=37480, start_index=37337, title='Structural Insights into the Protein Mannosyltransferase from Mycobacterium tuberculosis reveal a WW-Domain-Like Protein Motif in Bacteria - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12331936/#:~:text=We%20have%20previously%20demonstrated%20that,like%20domain')
89. AnnotationURLCitation(end_index=37909, start_index=37719, title='Structural Insights into the Protein Mannosyltransferase from Mycobacterium tuberculosis reveal a WW-Domain-Like Protein Motif in Bacteria - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12331936/#:~:text=differences%2C%20MtPMT%20shares%20functional%20homologies,its%20potential%20evolutionary%20linkage%20with')
90. AnnotationURLCitation(end_index=38397, start_index=38207, title='Structural Insights into the Protein Mannosyltransferase from Mycobacterium tuberculosis reveal a WW-Domain-Like Protein Motif in Bacteria - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12331936/#:~:text=differences%2C%20MtPMT%20shares%20functional%20homologies,its%20potential%20evolutionary%20linkage%20with')
91. AnnotationURLCitation(end_index=38639, start_index=38501, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=of%20plexins%20and%20transmembrane%20receptor,%282019')
92. AnnotationURLCitation(end_index=39855, start_index=39746, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=150,PMC%20free%20article')
93. AnnotationURLCitation(end_index=41431, start_index=41251, title='Recent advancements in understanding mammalian O-mannosylation | Glycobiology | Oxford Academic', type='url_citation', url='https://academic.oup.com/glycob/article-abstract/27/9/806/3914559#:~:text=Recent%20advancements%20in%20understanding%20mammalian,283%20%3A%2033026%20%E2%80%93')
94. AnnotationURLCitation(end_index=42206, start_index=42084, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=proteins%20with%20O,24%29%2C%20in%20a')
95. AnnotationURLCitation(end_index=42343, start_index=42207, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=yeast%20PMT4%20and%20PMT2%20O,8%3B%20%2011%20Larsen')
96. AnnotationURLCitation(end_index=42891, start_index=42753, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=of%20plexins%20and%20transmembrane%20receptor,%282019')
97. AnnotationURLCitation(end_index=43363, start_index=43240, title='Removal of pomt1 in zebrafish leads to loss of α-dystroglycan glycosylation and dystroglycanopathy phenotypes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=most%20common%20causes%20of%20a,Here%2C%20we')
98. AnnotationURLCitation(end_index=43514, start_index=43364, title='Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology')
99. AnnotationURLCitation(end_index=44026, start_index=43845, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=presumed%20heterodimer%20configuration%2C%20analogous%20to,2004%3B%20%2026%20Larsen%20et%C2%A0al')
100. AnnotationURLCitation(end_index=44184, start_index=44027, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=elsewhere%3B%20Nakamura%20et%C2%A0al,24%3B%20%2026%20Larsen%20et%C2%A0al')
101. AnnotationURLCitation(end_index=44974, start_index=44838, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=yeast%20PMT4%20and%20PMT2%20O,8%3B%20%2011%20Larsen')
102. AnnotationURLCitation(end_index=45083, start_index=44975, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=95,PMC%20free%20article')
103. AnnotationURLCitation(end_index=45432, start_index=45303, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=Targeted%20inactivation%20of%20Pomt1%20has,54')
104. AnnotationURLCitation(end_index=45565, start_index=45433, title='Removal of pomt1 in zebrafish leads to loss of α-dystroglycan glycosylation and dystroglycanopathy phenotypes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=Biallelic%20mutations%20in%20Protein%20O,Here%2C%20we')
105. AnnotationURLCitation(end_index=45963, start_index=45805, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=comprised%20of%20two%20protein%20O,recognition%20appears%20to%20rely%20on')
106. AnnotationURLCitation(end_index=46260, start_index=46113, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=Drosophila%20orthologues%20of%20mammalian%20POMT1,Blanco%20and')
107. AnnotationURLCitation(end_index=46588, start_index=46418, title='High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=match%20at%20L558%20relevantly%2C%20POMT1,mannosylation%20step%20cannot%20take%20place')
108. AnnotationURLCitation(end_index=46939, start_index=46783, title='High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=The%20asterisks%20mark%20the%20four,in%20all%20the%20lineages%20analysed')
109. AnnotationURLCitation(end_index=47111, start_index=46940, title='High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=Nematoda%2C%20there%20are%20no%20POMT1%2FPOMT2,and%20to%20a%20different%20glycosylation')
110. AnnotationURLCitation(end_index=47461, start_index=47305, title='High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=The%20asterisks%20mark%20the%20four,in%20all%20the%20lineages%20analysed')
111. AnnotationURLCitation(end_index=48817, start_index=48694, title='Removal of pomt1 in zebrafish leads to loss of α-dystroglycan glycosylation and dystroglycanopathy phenotypes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=most%20common%20causes%20of%20a,Here%2C%20we')
112. AnnotationURLCitation(end_index=48968, start_index=48818, title='Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/39789642/#:~:text=processing%20and%20O,system%20and%20skeletal%20muscle%20pathophysiology')
113. AnnotationURLCitation(end_index=49285, start_index=49163, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=proteins%20with%20O,24%29%2C%20in%20a')
114. AnnotationURLCitation(end_index=49467, start_index=49286, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=presumed%20heterodimer%20configuration%2C%20analogous%20to,2004%3B%20%2026%20Larsen%20et%C2%A0al')
115. AnnotationURLCitation(end_index=49816, start_index=49680, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=yeast%20PMT4%20and%20PMT2%20O,8%3B%20%2011%20Larsen')
116. AnnotationURLCitation(end_index=49925, start_index=49817, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=95,PMC%20free%20article')
117. AnnotationURLCitation(end_index=50192, start_index=50060, title='Removal of pomt1 in zebrafish leads to loss of α-dystroglycan glycosylation and dystroglycanopathy phenotypes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=Biallelic%20mutations%20in%20Protein%20O,Here%2C%20we')
118. AnnotationURLCitation(end_index=50505, start_index=50353, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=Mutations%20in%20the%20O,the%20severe%20condition%20Walker%20Warburg')
119. AnnotationURLCitation(end_index=50617, start_index=50506, title='Muscular dystrophies due to defective glycosylation of dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2949305/#:~:text=32%20were%20novel,Table%201')
120. AnnotationURLCitation(end_index=50953, start_index=50793, title='High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=The%20initial%20mannosylation%20reaction%20of,mannosyltransferase%20activity')
121. AnnotationURLCitation(end_index=51050, start_index=50954, title='High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=POMT1,Q8NCR0')
122. AnnotationURLCitation(end_index=51313, start_index=51181, title='Removal of pomt1 in zebrafish leads to loss of α-dystroglycan glycosylation and dystroglycanopathy phenotypes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=Biallelic%20mutations%20in%20Protein%20O,Here%2C%20we')
123. AnnotationURLCitation(end_index=51457, start_index=51314, title='Removal of pomt1 in zebrafish leads to loss of α-dystroglycan glycosylation and dystroglycanopathy phenotypes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38272461/#:~:text=extracellular%20matrix%20%28ECM%29,Muscle%20disease%2C%20retinal')
124. AnnotationURLCitation(end_index=51723, start_index=51633, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=,type')
125. AnnotationURLCitation(end_index=51897, start_index=51724, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=phosphatases%2C%20is%20a%20functional%20substrate,wiring%20phenotype%2C%20as%20well%20as')
126. AnnotationURLCitation(end_index=52209, start_index=52049, title='High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8478517/#:~:text=The%20initial%20mannosylation%20reaction%20of,mannosyltransferase%20activity')
127. AnnotationURLCitation(end_index=52445, start_index=52336, title='Protein O-mannosylation: one sugar, several pathways, many functions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10859634/#:~:text=150,PMC%20free%20article')